Lupin Gets CDSCO Panel nod To study LUBT017 Biosimilar to Eylea Dr. Divya Colin15 Oct 2022 6:00 PM ISTNew Delhi: Directing to appoint an independent data safety monitoring committee, the Subject Expert Committee (SEC) functional under Central Drug...
IQVIA Gets CDSCO Panel Nod To Study AVT06 biosimilar candidate to Eylea Dr. Divya Colin9 Oct 2022 1:40 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted permission to the...
Bayer Eylea approved in Japan for treatment of preterm infants with retinopathy of prematurity Ruchika Sharma28 Sept 2022 11:34 AM ISTRetinopathy of prematurity is a rare eye disease that affects the vessels in the retina of premature infants and is the leading cause of visual...
Ranibizumab switch from aflibercept in nAMD patients linked to deterioration in visual acuity: Study Dr. Kamal Kant Kohli22 Sept 2022 8:00 PM ISTUSA: Switching from aflibercept to ranibizumab resulted in a reduction in visual acuity and worse anatomic results in patients with neovascular...
Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines Ruchika Sharma7 Sept 2022 11:45 AM ISTThis agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three...
Aflibercept increases retinal nonperfusion in eyes with proliferative diabetic retinopathy: Study Dr. Hiral patel12 Aug 2022 8:00 PM ISTTexas: Aflibercept 2mg, administered intravitreal monthly or quarterly resulted in a significant increase in retinal nonperfusion (RNP) in patients...
Shilpa Biologicals gets NoC to conduct trials of biosimilar Aflibercept Ruchika Sharma26 April 2022 3:55 PM ISTBiosimilar Aflibercept is the second biosimilar product from SML that has entered the clinical trial phase after Biosimilar Adalimumab.
Aflibercept Improves Contrast sensitivity in Diabetic Macular Edema MD Bureau25 Jan 2022 9:00 AM ISTDiabetic macular edema (DME) is the most common cause of decreased best-corrected visual acuity (BCVA) and irreversible vision loss, with up to 10% of...
Aflibercept superior to PRP for Retinal Neovascularization in Diabetic Retinopathy: CLARITY Trial Dr Ishan Kataria27 May 2021 8:15 AM ISTProliferative diabetic retinopathy (PDR) is a common cause of visual impairment in people with diabetes. It is characterized by neovascularization...
Cipla Gulf expands partnership with Alvotech for commercialization of 4 biosimilar medicines in Australia, New Zealand Ruchika Sharma2 March 2021 4:26 PM ISTMumbai: Cipla Limited today announced that the company's subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf') is expanding its partnership with Alvotech for...
